| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ETV6 |
| Uniprot No | P41212 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-452aa |
| 氨基酸序列 | MSETPAQCSIKQERISYTPPESPVPSYASSTPLHVPVPRALRMEEDSIRLPAHLRLQPIYWSRDDVAQWLKWAENEFSLRPIDSNTFEMNGKALLLLTKEDFRYRSPHSGDVLYELLQHILKQRKPRILFSPFFHPGNSIHTQPEVILHQNHEEDNCVQRTPRPSVDNVHHNPPTIELLHRSRSPITTNHRPSPDPEQRPLRSPLDNMIRRLSPAERAQGPRPHQENNHQESYPLSVSPMENNHCPASSESHPKPSSPRQESTRVIQLMPSPIMHPLILNPRHSVDFKQSRLSEDGLHREGKPINLSHREDLAYMNHIMVSVSPPEEHAMPIGRIADCRLLWDYVYQLLSDSRYENFIRWEDKESKIFRIVDPNGLARLWGNHKNRTNMTYEKMSRALRHYYKLNIIRKEPGQRLLFRFMKTPDEIMSGRTDRLEHLESQELDEQIYQEDEC |
| 分子量 | 75.46 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3条关于重组人ETV6蛋白的参考文献及其摘要概括：
1. **《ETV6-AML1 Fusion Gene Analysis in Childhood Acute Lymphoblastic Leukemia》**
**作者：Golub et al.**
摘要：研究揭示了ETV6基因与AML1的染色体易位形成融合蛋白的机制，重组ETV6-AML1蛋白通过干扰正常造血细胞分化，导致儿童急性淋巴细胞白血病的发生。
2. **《The Oligomerization Domains of ETV6 Mediate Aberrant Protein Interactions in Leukemia》**
**作者：Poirel et al.**
摘要：分析重组ETV6蛋白的SAM结构域(Self-Association Motif)，发现其异常寡聚化能力可破坏转录调控功能，并与白血病的蛋白互作网络失调相关。
3. **《ETV6 as a Tumor Suppressor in Myeloid Neoplasms》**
**作者：Izraeli et al.**
摘要：探讨重组人ETV6蛋白在骨髓增生异常综合征中的作用，指出其通过抑制酪氨酸激酶信号通路(如PDGFRβ)的过度激活来维持细胞稳态，功能缺失导致肿瘤发生。
Recombinant human ETV6 protein is derived from the ETV6 (ETS variant transcription factor 6) gene, a member of the ETS family of transcription factors that regulate gene expression by binding to DNA. First identified in the 1990s, ETV6 plays critical roles in embryonic development, hematopoiesis, and cellular differentiation. It contains two key domains: a pointed (PNT) domain, involved in protein oligomerization, and an ETS domain, mediating DNA binding. Dysregulation of ETV6. particularly through chromosomal translocations (e.g., with ABL1. NTRK3. or RUNX1), is implicated in hematologic malignancies like leukemia and rare solid tumors. These translocations often produce oncogenic fusion proteins that drive uncontrolled proliferation.
The recombinant form of ETV6 is engineered using expression systems (e.g., bacteria, mammalian cells) to produce purified protein for functional studies. Researchers employ it to investigate interactions with DNA, co-regulators, or signaling pathways, shedding light on its role in normal physiology and disease. It is also used to screen inhibitors targeting ETV6 fusion oncoproteins or to develop diagnostic tools. Additionally, truncated ETV6 proteins (e.g., lacking the ETS domain) may serve as decoys to disrupt oncogenic signaling. Despite its association with cancer, native ETV6 acts as a tumor suppressor in certain contexts, highlighting the complexity of its biological functions. Studies on recombinant ETV6 continue to inform therapeutic strategies for malignancies linked to ETV6 aberrations.
×
